AddLife acquires DACH Medical Group, active in advanced surgery
Today, AddLife has signed an agreement to acquire all shares in DACH Medical Group Holding AG (“DACH”). DACH is the parent company in a group with net sales of approximately EUR 14 million, with operations in the advanced surgery product area. The business is conducted in Austria, Switzerland and Germany in a segment in which AddLife is already established as a supplier in the Nordic and Central European markets.
DACH Medical Group markets and sells both own brands and products from leading suppliers in advanced surgery such as laparoscopy and endoscopy, urology, thoracic medicine and gynaecology. The products are sold to customers in both public and privately funded care in Austria, Switzerland and Germany. The acquisition is a good complement to existing operations in advanced surgery at AddLife.
DACH’s operates with own salesforce in all three countries and the business has 23 employees with a total net sales of approximately EUR 14 million.
“The acquisition of DACH Medical Group means that we are strengthening our presence in Central Europe in an attractive segment where we already have major expertise and market presence in several markets,” says Kristina Willgård, CEO of AddLife AB.
The acquisition is expected to have only a marginally positive effect on AddLife’s earnings per share in the 2020 financial year.
Stockholm, 1 October 2020
AddLife AB (publ.)
For further information, please contact
Kristina Willgård, CEO, AddLife AB, +46 705 10 12 23
AddLife is an independent operator in Life Science that offers high-quality products, services and consulting to both the private and public sectors, mainly in the Nordic region and also in the rest of Europe. AddLife has about 1,000 employees in around 45 subsidiaries, which operate under their own brands. The Group has annual sales of approximately SEK 4.1 billion. AddLife is listed on the NASDAQ Stockholm stock exchange.
This information was issued for publication on 1 October 2020 at 14:30 pm CET.